{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:18:27Z","timestamp":1767374307681,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.01238","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T07:52:01Z","timestamp":1573631521000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Biological Approaches to Aggressive Cutaneous B-Cell Lymphomas"],"prefix":"10.3389","volume":"9","author":[{"given":"Giulia","family":"Tadiotto Cicogna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Ferranti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Lazzarotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Alaibac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/ddg.13164","article-title":"Cutaneous B-cell lymphomas\u2013pathogenesis, diagnostic workup, and therapy","volume":"14","author":"Nicolay","year":"2016","journal-title":"J Dtsch Dermatol Ges."},{"key":"B2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.12788\/j.sder.2018.014","article-title":"Primary cutaneous B-cell lymphomas\u2014clinical and histopathologic features, differential diagnosis, and treatment","volume":"37","author":"Chen","year":"2018","journal-title":"Semin Cutan Med Surg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1097\/PAS.0000000000000851","article-title":"Tumor microenvironment and checkpoint molecules in primary cutaneous diffuse large B-cell lymphoma\u2014new therapeutic targets","volume":"41","author":"Mitteldorf","year":"2017","journal-title":"Am J Surg Pathol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/modpathol.2013.156","article-title":"Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma","volume":"27","author":"Pham-Ledard","year":"2014","journal-title":"Mod Pathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.jid.2017.04.010","article-title":"Identification of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, leg type by massive parallel sequencing","volume":"137","author":"Mareschal","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1016\/j.jid.2019.05.008","article-title":"Mutations of the B-cell receptor pathway confer chemoresistance in primary cutaneous diffuse large B-cell lymphoma leg-type","volume":"139","author":"Ducharme","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jid.2018.04.038","article-title":"Genomic analyses identify recurrent alterations in immune evasion genes in diffuse large B-cell lymphoma, leg type","volume":"138","author":"Zhou","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/asheducation-2007.1.233","article-title":"Monoclonal antibodies for B-cell lymphomas: rituximab and beyond","volume":"2007","author":"Bello","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B10","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"on behalf of the ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO clinical practice guidelines","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/ejh.12315","article-title":"Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas","volume":"93","author":"Fabbri","year":"2014","journal-title":"Eur J Haematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1749-6632.2012.06661.x","article-title":"Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies","volume":"1263","author":"Gupta","year":"2012","journal-title":"Ann N Y Acad Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4081\/rt.2015.6067","article-title":"Excellent outcome of immunomodulation or Bruton's tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"7","author":"Gupta","year":"2015","journal-title":"Rare Tumors."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.clml.2014.11.003","article-title":"Treatment response of cutaneous mantle cell lymphoma to ibrutinib and radiotherapy","volume":"15","author":"Mancebo","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/bjh.16211","article-title":"Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"187","author":"Di Raimondo","year":"2019","journal-title":"Br J Haematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/PAS.0000000000000983","article-title":"PD-L1 and PD-L2 are differentially expressed by macrophages or tumor cells in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"42","author":"Menguy","year":"2018","journal-title":"Am J Surg Pathol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s12185-012-1198-3","article-title":"Diffuse large B cell lymphoma: molecular targeted therapy","volume":"96","author":"Roschewski","year":"2012","journal-title":"Int J Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1756-8722-7-44","article-title":"A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors","volume":"7","author":"De Vos","year":"2014","journal-title":"J Hematol Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/17474086.2017.1350164","article-title":"Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma","volume":"10","author":"Chiappella","year":"2017","journal-title":"Expert Rev Hematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.2217\/fon-2018-0325","article-title":"Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia","volume":"14","author":"Gbadamosi","year":"2018","journal-title":"Fut Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/16078454.2018.1549802","article-title":"Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis","volume":"24","author":"Yu","year":"2019","journal-title":"Hematology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s40265-017-0690-8","article-title":"Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B-cell malignancies","volume":"77","author":"Hay","year":"2017","journal-title":"Drugs."},{"key":"B23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41417-018-0073-7","article-title":"Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma","volume":"26","author":"Bao","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell non-hodgkin lymphoma","volume":"9","author":"Yaqing","year":"2019","journal-title":"Front Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"E1758","DOI":"10.3390\/ijms19061758","article-title":"Molecular mechanisms of disease progression in primary cutaneous diffuse large B-cell lymphoma, leg type during ibrutinib therapy","volume":"19","author":"Fox","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jid.2018.03.1516","article-title":"A single-arm phase II trial of lenalidomide in relapsing or refractory primary cutaneous large B-cell lymphoma, leg type","volume":"138","author":"Beylot-Barry","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1182\/blood-2009-05-220889","article-title":"Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2","volume":"114","author":"Gupta","year":"2009","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11523-018-0560-7","article-title":"Targeting BCL-2 in hematologic malignancies","volume":"13","author":"Khan","year":"2018","journal-title":"Target Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01238\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T07:52:02Z","timestamp":1573631522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01238\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":29,"alternative-id":["10.3389\/fonc.2019.01238"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.01238","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2019,11,13]]},"article-number":"1238"}}